Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 5c419a4b-5654-43dc-aefb-9e8e86bd5761

YUSIMRY

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-10-31
Captured
2026-09-09T23:37:47.659725+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue YUSIMRY if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before YUSIMRY use and during therapy. Initiate treatment for latent TB prior to YUSIMRY use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with YUSIMRY prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with YUSIMRY, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 ) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 ) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 ) ]. WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning . SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue YUSIMRY if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting YUSIMRY. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ]. 1.7 Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.
Full extracted label fields
application numbers
  1. BLA761216
boxed warning exact
  1. WARNING: SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ) ]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue YUSIMRY if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before YUSIMRY use and during therapy. Initiate treatment for latent TB prior to YUSIMRY use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with YUSIMRY prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with YUSIMRY, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 ) ]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products [see Warnings and Precautions ( 5.2 ) ]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including adalimumab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 ) ]. WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning . SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue YUSIMRY if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting YUSIMRY. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.
brand names
  1. YUSIMRY
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4cab600d-6950-409f-a6d8-d447da22cd95
generic names
  1. ADALIMUMAB-AQVH
id
5c419a4b-5654-43dc-aefb-9e8e86bd5761
indications and usage exact
  1. 1 INDICATIONS AND USAGE YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ]. 1.7 Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Meitheal Pharmaceuticals Inc.
    matched search terms
    1. tumor
    package ndcs
    1. 71288-816-81
    2. 71288-815-81
    product ndcs
    1. 71288-815
    2. 71288-816
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
    1. Warnings and Precautions, Autoimmunity ( 5.9 ) 7/2025
    record type
    complete_spl_indications_section_candidate
    routes
    1. SUBCUTANEOUS
    rxcuis
    1. 2640389
    2. 2640395
    3. 2640397
    4. 2640400
    source batch
    file
    /private/tmp/cancer-full-research/indications/raw/labels-00300.json
    meta
    disclaimer
    Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
    last updated
    2026-09-09
    results
    limit
    100
    skip
    300
    total
    830
    sha256
    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
    url
    https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=300&sort=id%3Aasc
    source url
    https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
    spl effective date
    2025-10-31
    spl effective time
    20251031
    spl set id
    4cab600d-6950-409f-a6d8-d447da22cd95
    spl version
    6
    substance names
    1. ADALIMUMAB
    uniis
    1. FYS6T7F842
    verification flags
    1. oncology_keyword_candidate_not_clinically_classified
    2. spl_text_not_verified_identical_to_latest_approved_label
    3. individual_indications_not_split_or_reconciled
    4. fda_label_posted_after_spl_effective_date_requires_version_review
    Drugs@FDA application source records
    1. application number
      BLA761216
      payload
      all indexed label documents
      1. Appl No
        761216
        Application Docs Date
        2021-12-20 00:00:00
        Application Docs ID
        69640
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        1
        Submission Type
        ORIG
      2. Appl No
        761216
        Application Docs Date
        2023-02-28 00:00:00
        Application Docs ID
        73621
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        1
        Submission Type
        SUPPL
      3. Appl No
        761216
        Application Docs Date
        2023-04-03 00:00:00
        Application Docs ID
        73929
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        3
        Submission Type
        SUPPL
      4. Appl No
        761216
        Application Docs Date
        2023-09-14 00:00:00
        Application Docs ID
        75463
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        4
        Submission Type
        SUPPL
      5. Appl No
        761216
        Application Docs Date
        2025-11-12 00:00:00
        Application Docs ID
        84141
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        7
        Submission Type
        SUPPL
      6. Appl No
        761216
        Application Docs Date
        2026-09-01 00:00:00
        Application Docs ID
        87118
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        10
        Submission Type
        SUPPL
      all submission records
      1. Appl No
        761216
        Review Priority
        STANDARD
        Submission Class Code ID
        9
        Submission No
        1
        Submission Status
        AP
        Submission Status Date
        2021-12-17 00:00:00
        Submission Type
        ORIG
        Submissions Public Notes
      2. Appl No
        761216
        Review Priority
        STANDARD
        Submission Class Code ID
        2
        Submission No
        1
        Submission Status
        AP
        Submission Status Date
        2023-02-27 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      3. Appl No
        761216
        Review Priority
        STANDARD
        Submission Class Code ID
        19
        Submission No
        3
        Submission Status
        AP
        Submission Status Date
        2023-03-31 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      4. Appl No
        761216
        Review Priority
        UNKNOWN
        Submission Class Code ID
        1
        Submission No
        4
        Submission Status
        AP
        Submission Status Date
        2023-09-13 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      5. Appl No
        761216
        Review Priority
        Submission Class Code ID
        28
        Submission No
        7
        Submission Status
        AP
        Submission Status Date
        2025-11-10 00:00:00
        Submission Type
        SUPPL
        Submissions Public Notes
      6. Appl No
        761216
        Review Priority
        STANDARD
        Submission Class Code ID
        3
        Submission No
        10
        Submission Status
        AP
        Submission Status Date
        Submission Type
        SUPPL
        Submissions Public Notes
      application number
      BLA761216
      approval interpretation
      Application linkage and approved submission are not indication-level current approval verification
      current indication status
      not_reconciled
      has approved submission record
      true
      latest approved submission date
      2025-11-10
      latest label selection rule
      max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
      latest posted label documents
      1. Appl No
        761216
        Application Docs Date
        2026-09-01 00:00:00
        Application Docs ID
        87118
        Application Docs Title
        0
        Application Docs Type ID
        2
        Submission No
        10
        Submission Type
        SUPPL
      official application record
      Appl No
      761216
      Appl Public Notes
      Appl Type
      BLA
      Sponsor Name
      EMERGE BIOSCIENCE PTE LTD
      openfda application present
      true
      products
      1. Active Ingredient
        ADALIMUMAB-AQVH
        Appl No
        761216
        Drug Name
        YUSIMRY
        Form
        INJECTABLE;INJECTION
        Product No
        001
        Reference Drug
        0
        Reference Standard
        0
        Strength
        40MG
        marketing status
        1. Prescription

    Source passages and status connections

    Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

    Passage 1 · positive indication candidate
    application numbers
    1. BLA761216
    brand names
    1. YUSIMRY
    classification reasons
    1. explicit_positive_indication_predicate
    2. tumor_or_malignant_hematology_words_in_positive_statement
    clinical review status
    pending
    content role
    positive_indication_candidate
    context span
    end
    507
    end exclusive
    true
    exact text
    1 INDICATIONS AND USAGE YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
    label id
    5c419a4b-5654-43dc-aefb-9e8e86bd5761
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
    start
    0
    current approval status
    not_reconciled
    duplicate text group
    dup-c274739a476ffab897ff
    extraction review status
    automated_candidate_pending_source_review
    generic names
    1. ADALIMUMAB-AQVH
    id
    ind-span-824b45a5a9a7250f653e
    label id
    5c419a4b-5654-43dc-aefb-9e8e86bd5761
    positive predicate support span
    end
    82
    end exclusive
    true
    exact text
    is a tumor necrosis factor (TNF) blocker indicated
    label id
    5c419a4b-5654-43dc-aefb-9e8e86bd5761
    offset unit
    unicode_code_points
    source array index
    0
    source field
    indications_and_usage_exact
    source text sha256
    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
    start
    32
    qualifier mentions
    1. context exact
      on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
      kind
      age
      polarity
      not_inferred
      span
      end
      249
      end exclusive
      true
      exact text
      adult patients
      label id
      5c419a4b-5654-43dc-aefb-9e8e86bd5761
      offset unit
      unicode_code_points
      source array index
      0
      source field
      indications_and_usage_exact
      source text sha256
      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
      start
      235
    regulatory links
      schema version
      0.1.0
      source batch sha256
      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
      source defined aliases
        source span
        end
        307
        end exclusive
        true
        exact text
        1 INDICATIONS AND USAGE YUSIMRY is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis .
        label id
        5c419a4b-5654-43dc-aefb-9e8e86bd5761
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
        start
        0
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
        spl effective date
        2025-10-31
        spl set id
        4cab600d-6950-409f-a6d8-d447da22cd95
        spl version
        6
        structured fields status
        not_extracted_no_values_inferred_from_mentions
        structured indication
        age
        Source null
        approval pathway
        Source null
        biomarker and test
        Source null
        disease stage
        Source null
        limitations
        Source null
        line
        Source null
        prior therapy
        Source null
        regimen
        Source null
        tumor histology
        Source null
        use intent
        tumor_directed_candidate
        Passage 2 · unclassified context
        application numbers
        1. BLA761216
        brand names
        1. YUSIMRY
        classification reasons
        1. no_unambiguous_positive_indication_predicate
        clinical review status
        pending
        content role
        unclassified_context
        context span
        end
        658
        end exclusive
        true
        exact text
        ymptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and sy
        label id
        5c419a4b-5654-43dc-aefb-9e8e86bd5761
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
        start
        108
        current approval status
        not_reconciled
        duplicate text group
        dup-da3406ca28c61d65a08b
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. ADALIMUMAB-AQVH
        id
        ind-span-045237c808587ff9bf88
        label id
        5c419a4b-5654-43dc-aefb-9e8e86bd5761
        positive predicate support span
        Source null
        qualifier mentions
        1. context exact
          ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
          kind
          age
          polarity
          not_inferred
          span
          end
          447
          end exclusive
          true
          exact text
          2 years of age
          label id
          5c419a4b-5654-43dc-aefb-9e8e86bd5761
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
          start
          433
        regulatory links
          schema version
          0.1.0
          source batch sha256
          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
          source defined aliases
            source span
            end
            458
            end exclusive
            true
            exact text
            ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
            label id
            5c419a4b-5654-43dc-aefb-9e8e86bd5761
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
            start
            308
            source url
            https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
            spl effective date
            2025-10-31
            spl set id
            4cab600d-6950-409f-a6d8-d447da22cd95
            spl version
            6
            structured fields status
            not_extracted_no_values_inferred_from_mentions
            structured indication
            age
            Source null
            approval pathway
            Source null
            biomarker and test
            Source null
            disease stage
            Source null
            limitations
            Source null
            line
            Source null
            prior therapy
            Source null
            regimen
            Source null
            tumor histology
            Source null
            use intent
            unclear
            Passage 3 · positive indication candidate
            application numbers
            1. BLA761216
            brand names
            1. YUSIMRY
            classification reasons
            1. inherited_predicate_from_same_label_section_requires_review
            2. no_tumor_directed_keyword_in_positive_statement
            clinical review status
            pending
            content role
            positive_indication_candidate
            context span
            end
            828
            end exclusive
            true
            exact text
            rately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years
            label id
            5c419a4b-5654-43dc-aefb-9e8e86bd5761
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
            start
            259
            current approval status
            not_reconciled
            duplicate text group
            dup-7d3c73ee4ea5d776c664
            extraction review status
            automated_candidate_pending_source_review
            generic names
            1. ADALIMUMAB-AQVH
            id
            ind-span-4f7109677f9a496ce4e0
            label id
            5c419a4b-5654-43dc-aefb-9e8e86bd5761
            positive predicate support span
            end
            82
            end exclusive
            true
            exact text
            is a tumor necrosis factor (TNF) blocker indicated
            label id
            5c419a4b-5654-43dc-aefb-9e8e86bd5761
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
            start
            32
            qualifier mentions
            1. context exact
              on of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
              kind
              age
              polarity
              not_inferred
              span
              end
              594
              end exclusive
              true
              exact text
              adult patients
              label id
              5c419a4b-5654-43dc-aefb-9e8e86bd5761
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
              start
              580
            regulatory links
              schema version
              0.1.0
              source batch sha256
              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
              source defined aliases
                source span
                end
                628
                end exclusive
                true
                exact text
                ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
                label id
                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                start
                459
                source url
                https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                spl effective date
                2025-10-31
                spl set id
                4cab600d-6950-409f-a6d8-d447da22cd95
                spl version
                6
                structured fields status
                not_extracted_no_values_inferred_from_mentions
                structured indication
                age
                Source null
                approval pathway
                Source null
                biomarker and test
                Source null
                disease stage
                Source null
                limitations
                Source null
                line
                Source null
                prior therapy
                Source null
                regimen
                Source null
                tumor histology
                Source null
                use intent
                non_oncology_or_unclear_candidate
                Passage 4 · positive indication candidate
                application numbers
                1. BLA761216
                brand names
                1. YUSIMRY
                classification reasons
                1. inherited_predicate_from_same_label_section_requires_review
                2. no_tumor_directed_keyword_in_positive_statement
                clinical review status
                pending
                content role
                positive_indication_candidate
                context span
                end
                919
                end exclusive
                true
                exact text
                nts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
                label id
                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                start
                429
                current approval status
                not_reconciled
                duplicate text group
                dup-e249feb230bd96aef154
                extraction review status
                automated_candidate_pending_source_review
                generic names
                1. ADALIMUMAB-AQVH
                id
                ind-span-3ef7e75ba17e1e49eb6d
                label id
                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                positive predicate support span
                end
                82
                end exclusive
                true
                exact text
                is a tumor necrosis factor (TNF) blocker indicated
                label id
                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                start
                32
                qualifier mentions
                1. context exact
                  ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                  kind
                  age
                  polarity
                  not_inferred
                  span
                  end
                  682
                  end exclusive
                  true
                  exact text
                  adult patients
                  label id
                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                  start
                  668
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                  source defined aliases
                    source span
                    end
                    719
                    end exclusive
                    true
                    exact text
                    ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                    label id
                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                    start
                    629
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                    spl effective date
                    2025-10-31
                    spl set id
                    4cab600d-6950-409f-a6d8-d447da22cd95
                    spl version
                    6
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    non_oncology_or_unclear_candidate
                    Passage 5 · positive indication candidate
                    application numbers
                    1. BLA761216
                    brand names
                    1. YUSIMRY
                    classification reasons
                    1. inherited_predicate_from_same_label_section_requires_review
                    2. no_tumor_directed_keyword_in_positive_statement
                    clinical review status
                    pending
                    content role
                    positive_indication_candidate
                    context span
                    end
                    1045
                    end exclusive
                    true
                    exact text
                    on of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or we
                    label id
                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                    start
                    520
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-4a8b964ba0b4e78d49e1
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. ADALIMUMAB-AQVH
                    id
                    ind-span-2c9d9bf532d310e9be85
                    label id
                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                    positive predicate support span
                    end
                    82
                    end exclusive
                    true
                    exact text
                    is a tumor necrosis factor (TNF) blocker indicated
                    label id
                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                    start
                    32
                    qualifier mentions
                    1. context exact
                      eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      796
                      end exclusive
                      true
                      exact text
                      adults
                      label id
                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                      start
                      790
                    2. context exact
                      moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      819
                      end exclusive
                      true
                      exact text
                      pediatric patients
                      label id
                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                      start
                      801
                    3. context exact
                      ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                      kind
                      age
                      polarity
                      not_inferred
                      span
                      end
                      834
                      end exclusive
                      true
                      exact text
                      6 years of age
                      label id
                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                      start
                      820
                    regulatory links
                      schema version
                      0.1.0
                      source batch sha256
                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                      source defined aliases
                        source span
                        end
                        845
                        end exclusive
                        true
                        exact text
                        ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                        label id
                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                        start
                        720
                        source url
                        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                        spl effective date
                        2025-10-31
                        spl set id
                        4cab600d-6950-409f-a6d8-d447da22cd95
                        spl version
                        6
                        structured fields status
                        not_extracted_no_values_inferred_from_mentions
                        structured indication
                        age
                        Source null
                        approval pathway
                        Source null
                        biomarker and test
                        Source null
                        disease stage
                        Source null
                        limitations
                        Source null
                        line
                        Source null
                        prior therapy
                        Source null
                        regimen
                        Source null
                        tumor histology
                        Source null
                        use intent
                        non_oncology_or_unclear_candidate
                        Passage 6 · unclassified context
                        application numbers
                        1. BLA761216
                        brand names
                        1. YUSIMRY
                        classification reasons
                        1. no_unambiguous_positive_indication_predicate
                        clinical review status
                        pending
                        content role
                        unclassified_context
                        context span
                        end
                        1134
                        end exclusive
                        true
                        exact text
                        signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
                        label id
                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                        start
                        646
                        current approval status
                        not_reconciled
                        duplicate text group
                        dup-9d059b16681c3c13cd36
                        extraction review status
                        automated_candidate_pending_source_review
                        generic names
                        1. ADALIMUMAB-AQVH
                        id
                        ind-span-e5496f360eaa7f640103
                        label id
                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                        positive predicate support span
                        Source null
                        qualifier mentions
                        1. context exact
                          ment of moderately to severely active ulcerative colitis in adult patients.
                          kind
                          age
                          polarity
                          not_inferred
                          span
                          end
                          933
                          end exclusive
                          true
                          exact text
                          adult patients
                          label id
                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                          start
                          919
                        regulatory links
                          schema version
                          0.1.0
                          source batch sha256
                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                          source defined aliases
                            source span
                            end
                            934
                            end exclusive
                            true
                            exact text
                            ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients.
                            label id
                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                            start
                            846
                            source url
                            https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                            spl effective date
                            2025-10-31
                            spl set id
                            4cab600d-6950-409f-a6d8-d447da22cd95
                            spl version
                            6
                            structured fields status
                            not_extracted_no_values_inferred_from_mentions
                            structured indication
                            age
                            Source null
                            approval pathway
                            Source null
                            biomarker and test
                            Source null
                            disease stage
                            Source null
                            limitations
                            Source null
                            line
                            Source null
                            prior therapy
                            Source null
                            regimen
                            Source null
                            tumor histology
                            Source null
                            use intent
                            unclear
                            Passage 7 · limitation of use
                            application numbers
                            1. BLA761216
                            brand names
                            1. YUSIMRY
                            classification reasons
                            1. negative_or_not_established_clause
                            clinical review status
                            pending
                            content role
                            limitation_of_use
                            context span
                            end
                            1275
                            end exclusive
                            true
                            exact text
                            nt of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                            label id
                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                            start
                            735
                            current approval status
                            not_reconciled
                            duplicate text group
                            dup-a347515442935fd2c0af
                            extraction review status
                            automated_candidate_pending_source_review
                            generic names
                            1. ADALIMUMAB-AQVH
                            id
                            ind-span-d9a72c178bc809bd06b3
                            label id
                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                            positive predicate support span
                            Source null
                            qualifier mentions
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                source defined aliases
                                  source span
                                  end
                                  1075
                                  end exclusive
                                  true
                                  exact text
                                  ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
                                  label id
                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                  start
                                  935
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                  spl effective date
                                  2025-10-31
                                  spl set id
                                  4cab600d-6950-409f-a6d8-d447da22cd95
                                  spl version
                                  6
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  not_applicable
                                  Passage 8 · unclassified context
                                  application numbers
                                  1. BLA761216
                                  brand names
                                  1. YUSIMRY
                                  classification reasons
                                  1. no_unambiguous_positive_indication_predicate
                                  clinical review status
                                  pending
                                  content role
                                  unclassified_context
                                  context span
                                  end
                                  1475
                                  end exclusive
                                  true
                                  exact text
                                  y to severely active ulcerative colitis in adult patients. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthr
                                  label id
                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                  start
                                  876
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-f062b2d957866bfda706
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. ADALIMUMAB-AQVH
                                  id
                                  ind-span-18a55f726b7037dce4ef
                                  label id
                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                  1. context exact
                                    Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                    kind
                                    age
                                    polarity
                                    not_inferred
                                    span
                                    end
                                    1103
                                    end exclusive
                                    true
                                    exact text
                                    adult patients
                                    label id
                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                    start
                                    1089
                                  regulatory links
                                    schema version
                                    0.1.0
                                    source batch sha256
                                    bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                    source defined aliases
                                      source span
                                      end
                                      1275
                                      end exclusive
                                      true
                                      exact text
                                      Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                      label id
                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                      start
                                      1076
                                      source url
                                      https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                      spl effective date
                                      2025-10-31
                                      spl set id
                                      4cab600d-6950-409f-a6d8-d447da22cd95
                                      spl version
                                      6
                                      structured fields status
                                      not_extracted_no_values_inferred_from_mentions
                                      structured indication
                                      age
                                      Source null
                                      approval pathway
                                      Source null
                                      biomarker and test
                                      Source null
                                      disease stage
                                      Source null
                                      limitations
                                      Source null
                                      line
                                      Source null
                                      prior therapy
                                      Source null
                                      regimen
                                      Source null
                                      tumor histology
                                      Source null
                                      use intent
                                      unclear
                                      Passage 9 · unclassified context
                                      application numbers
                                      1. BLA761216
                                      brand names
                                      1. YUSIMRY
                                      classification reasons
                                      1. no_unambiguous_positive_indication_predicate
                                      clinical review status
                                      pending
                                      content role
                                      unclassified_context
                                      context span
                                      end
                                      1559
                                      end exclusive
                                      true
                                      exact text
                                      Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical r
                                      label id
                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                      offset unit
                                      unicode_code_points
                                      source array index
                                      0
                                      source field
                                      indications_and_usage_exact
                                      source text sha256
                                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                      start
                                      1076
                                      current approval status
                                      not_reconciled
                                      duplicate text group
                                      dup-2ca2a6b7229f634be35d
                                      extraction review status
                                      automated_candidate_pending_source_review
                                      generic names
                                      1. ADALIMUMAB-AQVH
                                      id
                                      ind-span-eceed14c55b15f79fe58
                                      label id
                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                      positive predicate support span
                                      Source null
                                      qualifier mentions
                                      1. context exact
                                        Treatment of moderate to severe hidradenitis suppurativa in adult patients.
                                        kind
                                        age
                                        polarity
                                        not_inferred
                                        span
                                        end
                                        1358
                                        end exclusive
                                        true
                                        exact text
                                        adult patients
                                        label id
                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                        start
                                        1344
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                        source defined aliases
                                          source span
                                          end
                                          1359
                                          end exclusive
                                          true
                                          exact text
                                          ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients.
                                          label id
                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                          start
                                          1276
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                          spl effective date
                                          2025-10-31
                                          spl set id
                                          4cab600d-6950-409f-a6d8-d447da22cd95
                                          spl version
                                          6
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          unclear
                                          Passage 10 · unclassified context
                                          application numbers
                                          1. BLA761216
                                          brand names
                                          1. YUSIMRY
                                          classification reasons
                                          1. no_unambiguous_positive_indication_predicate
                                          clinical review status
                                          pending
                                          content role
                                          unclassified_context
                                          context span
                                          end
                                          1646
                                          end exclusive
                                          true
                                          exact text
                                          candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functi
                                          label id
                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                          start
                                          1160
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-8f88d2cf2dda5dcf0922
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. ADALIMUMAB-AQVH
                                          id
                                          ind-span-ddf9d602da3da20926cb
                                          label id
                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                          positive predicate support span
                                          Source null
                                          qualifier mentions
                                          1. context exact
                                            f non-infectious intermediate, posterior, and panuveitis in adults.
                                            kind
                                            age
                                            polarity
                                            not_inferred
                                            span
                                            end
                                            1445
                                            end exclusive
                                            true
                                            exact text
                                            adults
                                            label id
                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                            start
                                            1439
                                          regulatory links
                                            schema version
                                            0.1.0
                                            source batch sha256
                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                            source defined aliases
                                              source span
                                              end
                                              1446
                                              end exclusive
                                              true
                                              exact text
                                              ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults.
                                              label id
                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                              start
                                              1360
                                              source url
                                              https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                              spl effective date
                                              2025-10-31
                                              spl set id
                                              4cab600d-6950-409f-a6d8-d447da22cd95
                                              spl version
                                              6
                                              structured fields status
                                              not_extracted_no_values_inferred_from_mentions
                                              structured indication
                                              age
                                              Source null
                                              approval pathway
                                              Source null
                                              biomarker and test
                                              Source null
                                              disease stage
                                              Source null
                                              limitations
                                              Source null
                                              line
                                              Source null
                                              prior therapy
                                              Source null
                                              regimen
                                              Source null
                                              tumor histology
                                              Source null
                                              use intent
                                              unclear
                                              Passage 11 · unclassified context
                                              application numbers
                                              1. BLA761216
                                              brand names
                                              1. YUSIMRY
                                              classification reasons
                                              1. no_unambiguous_positive_indication_predicate
                                              clinical review status
                                              pending
                                              content role
                                              unclassified_context
                                              context span
                                              end
                                              1654
                                              end exclusive
                                              true
                                              exact text
                                              medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in ad
                                              label id
                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                              start
                                              1247
                                              current approval status
                                              not_reconciled
                                              duplicate text group
                                              dup-20f05dad1eba391c7c5b
                                              extraction review status
                                              automated_candidate_pending_source_review
                                              generic names
                                              1. ADALIMUMAB-AQVH
                                              id
                                              ind-span-f7e138b83ec30d4646dc
                                              label id
                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                              positive predicate support span
                                              Source null
                                              qualifier mentions
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                  source defined aliases
                                                    source span
                                                    end
                                                    1454
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ( 1.9 )
                                                    label id
                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                    start
                                                    1447
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                    spl effective date
                                                    2025-10-31
                                                    spl set id
                                                    4cab600d-6950-409f-a6d8-d447da22cd95
                                                    spl version
                                                    6
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 12 · positive indication candidate
                                                    application numbers
                                                    1. BLA761216
                                                    brand names
                                                    1. YUSIMRY
                                                    classification reasons
                                                    1. explicit_positive_indication_predicate
                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                    clinical review status
                                                    pending
                                                    content role
                                                    positive_indication_candidate
                                                    context span
                                                    end
                                                    1923
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ly less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in adult patients. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults. ( 1.9 ) 1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducin
                                                    label id
                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                    start
                                                    1255
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-d7b36fa074ff24b88420
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. ADALIMUMAB-AQVH
                                                    id
                                                    ind-span-0c4fa13c63e3af6c70b9
                                                    label id
                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                    positive predicate support span
                                                    end
                                                    1500
                                                    end exclusive
                                                    true
                                                    exact text
                                                    is indicated
                                                    label id
                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                    start
                                                    1488
                                                    qualifier mentions
                                                    1. context exact
                                                      on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                      kind
                                                      age
                                                      polarity
                                                      not_inferred
                                                      span
                                                      end
                                                      1666
                                                      end exclusive
                                                      true
                                                      exact text
                                                      adult patients
                                                      label id
                                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                      offset unit
                                                      unicode_code_points
                                                      source array index
                                                      0
                                                      source field
                                                      indications_and_usage_exact
                                                      source text sha256
                                                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                      start
                                                      1652
                                                    regulatory links
                                                      schema version
                                                      0.1.0
                                                      source batch sha256
                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                      source defined aliases
                                                        source span
                                                        end
                                                        1723
                                                        end exclusive
                                                        true
                                                        exact text
                                                        1.1 Rheumatoid Arthritis YUSIMRY is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                        label id
                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                        start
                                                        1455
                                                        source url
                                                        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                        spl effective date
                                                        2025-10-31
                                                        spl set id
                                                        4cab600d-6950-409f-a6d8-d447da22cd95
                                                        spl version
                                                        6
                                                        structured fields status
                                                        not_extracted_no_values_inferred_from_mentions
                                                        structured indication
                                                        age
                                                        Source null
                                                        approval pathway
                                                        Source null
                                                        biomarker and test
                                                        Source null
                                                        disease stage
                                                        Source null
                                                        limitations
                                                        Source null
                                                        line
                                                        Source null
                                                        prior therapy
                                                        Source null
                                                        regimen
                                                        Source null
                                                        tumor histology
                                                        Source null
                                                        use intent
                                                        non_oncology_or_unclear_candidate
                                                        Passage 13 · unclassified context
                                                        application numbers
                                                        1. BLA761216
                                                        brand names
                                                        1. YUSIMRY
                                                        classification reasons
                                                        1. no_unambiguous_positive_indication_predicate
                                                        clinical review status
                                                        pending
                                                        content role
                                                        unclassified_context
                                                        context span
                                                        end
                                                        2056
                                                        end exclusive
                                                        true
                                                        exact text
                                                        symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and olde
                                                        label id
                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                        offset unit
                                                        unicode_code_points
                                                        source array index
                                                        0
                                                        source field
                                                        indications_and_usage_exact
                                                        source text sha256
                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                        start
                                                        1524
                                                        current approval status
                                                        not_reconciled
                                                        duplicate text group
                                                        dup-0c194bd0d6ccd8d77e79
                                                        extraction review status
                                                        automated_candidate_pending_source_review
                                                        generic names
                                                        1. ADALIMUMAB-AQVH
                                                        id
                                                        ind-span-44428d394b9e40eb4ab2
                                                        label id
                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                        positive predicate support span
                                                        Source null
                                                        qualifier mentions
                                                        1. context exact
                                                          YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                          kind
                                                          biomarker
                                                          polarity
                                                          not_inferred
                                                          span
                                                          end
                                                          1816
                                                          end exclusive
                                                          true
                                                          exact text
                                                          methotrexate or other non-biologic disease-
                                                          label id
                                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                          start
                                                          1773
                                                        2. context exact
                                                          YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                          kind
                                                          regimen
                                                          polarity
                                                          not_inferred
                                                          span
                                                          end
                                                          1855
                                                          end exclusive
                                                          true
                                                          exact text
                                                          in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
                                                          label id
                                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                          start
                                                          1753
                                                        regulatory links
                                                          schema version
                                                          0.1.0
                                                          source batch sha256
                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                          source defined aliases
                                                            source span
                                                            end
                                                            1856
                                                            end exclusive
                                                            true
                                                            exact text
                                                            YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                            label id
                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                            start
                                                            1724
                                                            source url
                                                            https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                            spl effective date
                                                            2025-10-31
                                                            spl set id
                                                            4cab600d-6950-409f-a6d8-d447da22cd95
                                                            spl version
                                                            6
                                                            structured fields status
                                                            not_extracted_no_values_inferred_from_mentions
                                                            structured indication
                                                            age
                                                            Source null
                                                            approval pathway
                                                            Source null
                                                            biomarker and test
                                                            Source null
                                                            disease stage
                                                            Source null
                                                            limitations
                                                            Source null
                                                            line
                                                            Source null
                                                            prior therapy
                                                            Source null
                                                            regimen
                                                            Source null
                                                            tumor histology
                                                            Source null
                                                            use intent
                                                            unclear
                                                            Passage 14 · positive indication candidate
                                                            application numbers
                                                            1. BLA761216
                                                            brand names
                                                            1. YUSIMRY
                                                            classification reasons
                                                            1. explicit_positive_indication_predicate
                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                            clinical review status
                                                            pending
                                                            content role
                                                            positive_indication_candidate
                                                            context span
                                                            end
                                                            2258
                                                            end exclusive
                                                            true
                                                            exact text
                                                            patients with moderately to severely active rheumatoid arthritis. YUSIMRY can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and impro
                                                            label id
                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                            start
                                                            1657
                                                            current approval status
                                                            not_reconciled
                                                            duplicate text group
                                                            dup-de35f2b657d87b9341b7
                                                            extraction review status
                                                            automated_candidate_pending_source_review
                                                            generic names
                                                            1. ADALIMUMAB-AQVH
                                                            id
                                                            ind-span-722570812581c9127d81
                                                            label id
                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                            positive predicate support span
                                                            end
                                                            1911
                                                            end exclusive
                                                            true
                                                            exact text
                                                            is indicated
                                                            label id
                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                            start
                                                            1899
                                                            qualifier mentions
                                                            1. context exact
                                                              ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                              kind
                                                              age
                                                              polarity
                                                              not_inferred
                                                              span
                                                              end
                                                              2047
                                                              end exclusive
                                                              true
                                                              exact text
                                                              2 years of age
                                                              label id
                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                              start
                                                              2033
                                                            regulatory links
                                                              schema version
                                                              0.1.0
                                                              source batch sha256
                                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                              source defined aliases
                                                                source span
                                                                end
                                                                2058
                                                                end exclusive
                                                                true
                                                                exact text
                                                                1.2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                                label id
                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                start
                                                                1857
                                                                source url
                                                                https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                spl effective date
                                                                2025-10-31
                                                                spl set id
                                                                4cab600d-6950-409f-a6d8-d447da22cd95
                                                                spl version
                                                                6
                                                                structured fields status
                                                                not_extracted_no_values_inferred_from_mentions
                                                                structured indication
                                                                age
                                                                Source null
                                                                approval pathway
                                                                Source null
                                                                biomarker and test
                                                                Source null
                                                                disease stage
                                                                Source null
                                                                limitations
                                                                Source null
                                                                line
                                                                Source null
                                                                prior therapy
                                                                Source null
                                                                regimen
                                                                Source null
                                                                tumor histology
                                                                Source null
                                                                use intent
                                                                non_oncology_or_unclear_candidate
                                                                Passage 15 · unclassified context
                                                                application numbers
                                                                1. BLA761216
                                                                brand names
                                                                1. YUSIMRY
                                                                classification reasons
                                                                1. no_unambiguous_positive_indication_predicate
                                                                clinical review status
                                                                pending
                                                                content role
                                                                unclassified_context
                                                                context span
                                                                end
                                                                2321
                                                                end exclusive
                                                                true
                                                                exact text
                                                                2 Juvenile Idiopathic Arthritis YUSIMRY is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic
                                                                label id
                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                start
                                                                1859
                                                                current approval status
                                                                not_reconciled
                                                                duplicate text group
                                                                dup-f7ad798ab6ec405e3bd4
                                                                extraction review status
                                                                automated_candidate_pending_source_review
                                                                generic names
                                                                1. ADALIMUMAB-AQVH
                                                                id
                                                                ind-span-4ae21cc60d4b3928030a
                                                                label id
                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                positive predicate support span
                                                                Source null
                                                                qualifier mentions
                                                                1. context exact
                                                                  YUSIMRY can be used alone or in combination with methotrexate.
                                                                  kind
                                                                  biomarker
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2120
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  methotrexate
                                                                  label id
                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                  start
                                                                  2108
                                                                2. context exact
                                                                  YUSIMRY can be used alone or in combination with methotrexate.
                                                                  kind
                                                                  regimen
                                                                  polarity
                                                                  not_inferred
                                                                  span
                                                                  end
                                                                  2120
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  in combination with methotrexate
                                                                  label id
                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                  start
                                                                  2088
                                                                regulatory links
                                                                  schema version
                                                                  0.1.0
                                                                  source batch sha256
                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                  source defined aliases
                                                                    source span
                                                                    end
                                                                    2121
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    YUSIMRY can be used alone or in combination with methotrexate.
                                                                    label id
                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                    start
                                                                    2059
                                                                    source url
                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                    spl effective date
                                                                    2025-10-31
                                                                    spl set id
                                                                    4cab600d-6950-409f-a6d8-d447da22cd95
                                                                    spl version
                                                                    6
                                                                    structured fields status
                                                                    not_extracted_no_values_inferred_from_mentions
                                                                    structured indication
                                                                    age
                                                                    Source null
                                                                    approval pathway
                                                                    Source null
                                                                    biomarker and test
                                                                    Source null
                                                                    disease stage
                                                                    Source null
                                                                    limitations
                                                                    Source null
                                                                    line
                                                                    Source null
                                                                    prior therapy
                                                                    Source null
                                                                    regimen
                                                                    Source null
                                                                    tumor histology
                                                                    Source null
                                                                    use intent
                                                                    unclear
                                                                    Passage 16 · positive indication candidate
                                                                    application numbers
                                                                    1. BLA761216
                                                                    brand names
                                                                    1. YUSIMRY
                                                                    classification reasons
                                                                    1. explicit_positive_indication_predicate
                                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                                    clinical review status
                                                                    pending
                                                                    content role
                                                                    positive_indication_candidate
                                                                    context span
                                                                    end
                                                                    2531
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    ng signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. YUSIMRY can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondyli
                                                                    label id
                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                    start
                                                                    1922
                                                                    current approval status
                                                                    not_reconciled
                                                                    duplicate text group
                                                                    dup-cea81833ef179cc4b720
                                                                    extraction review status
                                                                    automated_candidate_pending_source_review
                                                                    generic names
                                                                    1. ADALIMUMAB-AQVH
                                                                    id
                                                                    ind-span-d58895f96c4a6e07c839
                                                                    label id
                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                    positive predicate support span
                                                                    end
                                                                    2166
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    is indicated
                                                                    label id
                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                    start
                                                                    2154
                                                                    qualifier mentions
                                                                    1. context exact
                                                                      on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                      kind
                                                                      age
                                                                      polarity
                                                                      not_inferred
                                                                      span
                                                                      end
                                                                      2298
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      adult patients
                                                                      label id
                                                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                      start
                                                                      2284
                                                                    regulatory links
                                                                      schema version
                                                                      0.1.0
                                                                      source batch sha256
                                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                      source defined aliases
                                                                        source span
                                                                        end
                                                                        2331
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        1.3 Psoriatic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                        label id
                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                        start
                                                                        2122
                                                                        source url
                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                        spl effective date
                                                                        2025-10-31
                                                                        spl set id
                                                                        4cab600d-6950-409f-a6d8-d447da22cd95
                                                                        spl version
                                                                        6
                                                                        structured fields status
                                                                        not_extracted_no_values_inferred_from_mentions
                                                                        structured indication
                                                                        age
                                                                        Source null
                                                                        approval pathway
                                                                        Source null
                                                                        biomarker and test
                                                                        Source null
                                                                        disease stage
                                                                        Source null
                                                                        limitations
                                                                        Source null
                                                                        line
                                                                        Source null
                                                                        prior therapy
                                                                        Source null
                                                                        regimen
                                                                        Source null
                                                                        tumor histology
                                                                        Source null
                                                                        use intent
                                                                        non_oncology_or_unclear_candidate
                                                                        Passage 17 · unclassified context
                                                                        application numbers
                                                                        1. BLA761216
                                                                        brand names
                                                                        1. YUSIMRY
                                                                        classification reasons
                                                                        1. no_unambiguous_positive_indication_predicate
                                                                        clinical review status
                                                                        pending
                                                                        content role
                                                                        unclassified_context
                                                                        context span
                                                                        end
                                                                        2601
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        tic Arthritis YUSIMRY is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of mod
                                                                        label id
                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                        start
                                                                        2132
                                                                        current approval status
                                                                        not_reconciled
                                                                        duplicate text group
                                                                        dup-8068a0a336bd80812aac
                                                                        extraction review status
                                                                        automated_candidate_pending_source_review
                                                                        generic names
                                                                        1. ADALIMUMAB-AQVH
                                                                        id
                                                                        ind-span-fa591f58af2c1f141c1a
                                                                        label id
                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                        positive predicate support span
                                                                        Source null
                                                                        qualifier mentions
                                                                        1. context exact
                                                                          YUSIMRY can be used alone or in combination with non-biologic DMARDs.
                                                                          kind
                                                                          regimen
                                                                          polarity
                                                                          not_inferred
                                                                          span
                                                                          end
                                                                          2400
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          in combination with non-biologic DMARDs
                                                                          label id
                                                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                          start
                                                                          2361
                                                                        regulatory links
                                                                          schema version
                                                                          0.1.0
                                                                          source batch sha256
                                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                          source defined aliases
                                                                            source span
                                                                            end
                                                                            2401
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            YUSIMRY can be used alone or in combination with non-biologic DMARDs.
                                                                            label id
                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                            start
                                                                            2332
                                                                            source url
                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                            spl effective date
                                                                            2025-10-31
                                                                            spl set id
                                                                            4cab600d-6950-409f-a6d8-d447da22cd95
                                                                            spl version
                                                                            6
                                                                            structured fields status
                                                                            not_extracted_no_values_inferred_from_mentions
                                                                            structured indication
                                                                            age
                                                                            Source null
                                                                            approval pathway
                                                                            Source null
                                                                            biomarker and test
                                                                            Source null
                                                                            disease stage
                                                                            Source null
                                                                            limitations
                                                                            Source null
                                                                            line
                                                                            Source null
                                                                            prior therapy
                                                                            Source null
                                                                            regimen
                                                                            Source null
                                                                            tumor histology
                                                                            Source null
                                                                            use intent
                                                                            unclear
                                                                            Passage 18 · positive indication candidate
                                                                            application numbers
                                                                            1. BLA761216
                                                                            brand names
                                                                            1. YUSIMRY
                                                                            classification reasons
                                                                            1. explicit_positive_indication_predicate
                                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                                            clinical review status
                                                                            pending
                                                                            content role
                                                                            positive_indication_candidate
                                                                            context span
                                                                            end
                                                                            2735
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            hibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. YUSIMRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY i
                                                                            label id
                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                            start
                                                                            2202
                                                                            current approval status
                                                                            not_reconciled
                                                                            duplicate text group
                                                                            dup-0d3e4aa63233b53b2d3d
                                                                            extraction review status
                                                                            automated_candidate_pending_source_review
                                                                            generic names
                                                                            1. ADALIMUMAB-AQVH
                                                                            id
                                                                            ind-span-1d5f813a1377a3a84ee9
                                                                            label id
                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                            positive predicate support span
                                                                            end
                                                                            2449
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            is indicated
                                                                            label id
                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                            start
                                                                            2437
                                                                            qualifier mentions
                                                                            1. context exact
                                                                              tis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                              kind
                                                                              age
                                                                              polarity
                                                                              not_inferred
                                                                              span
                                                                              end
                                                                              2499
                                                                              end exclusive
                                                                              true
                                                                              exact text
                                                                              adult patients
                                                                              label id
                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                              offset unit
                                                                              unicode_code_points
                                                                              source array index
                                                                              0
                                                                              source field
                                                                              indications_and_usage_exact
                                                                              source text sha256
                                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                              start
                                                                              2485
                                                                            regulatory links
                                                                              schema version
                                                                              0.1.0
                                                                              source batch sha256
                                                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                              source defined aliases
                                                                                source span
                                                                                end
                                                                                2535
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                                label id
                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                start
                                                                                2402
                                                                                source url
                                                                                https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                spl effective date
                                                                                2025-10-31
                                                                                spl set id
                                                                                4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                spl version
                                                                                6
                                                                                structured fields status
                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                structured indication
                                                                                age
                                                                                Source null
                                                                                approval pathway
                                                                                Source null
                                                                                biomarker and test
                                                                                Source null
                                                                                disease stage
                                                                                Source null
                                                                                limitations
                                                                                Source null
                                                                                line
                                                                                Source null
                                                                                prior therapy
                                                                                Source null
                                                                                regimen
                                                                                Source null
                                                                                tumor histology
                                                                                Source null
                                                                                use intent
                                                                                non_oncology_or_unclear_candidate
                                                                                Passage 19 · positive indication candidate
                                                                                application numbers
                                                                                1. BLA761216
                                                                                brand names
                                                                                1. YUSIMRY
                                                                                classification reasons
                                                                                1. explicit_positive_indication_predicate
                                                                                2. no_tumor_directed_keyword_in_positive_statement
                                                                                clinical review status
                                                                                pending
                                                                                content role
                                                                                positive_indication_candidate
                                                                                context span
                                                                                end
                                                                                2902
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                MRY can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis YUSIMRY is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has no
                                                                                label id
                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                start
                                                                                2336
                                                                                current approval status
                                                                                not_reconciled
                                                                                duplicate text group
                                                                                dup-fbb60e8b0b8e00e30de0
                                                                                extraction review status
                                                                                automated_candidate_pending_source_review
                                                                                generic names
                                                                                1. ADALIMUMAB-AQVH
                                                                                id
                                                                                ind-span-2a6980a962b8eb5d04c9
                                                                                label id
                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                positive predicate support span
                                                                                end
                                                                                2576
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                is indicated
                                                                                label id
                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                start
                                                                                2564
                                                                                qualifier mentions
                                                                                1. context exact
                                                                                  eatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2653
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  adults
                                                                                  label id
                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                  start
                                                                                  2647
                                                                                2. context exact
                                                                                  moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2676
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  pediatric patients
                                                                                  label id
                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                  start
                                                                                  2658
                                                                                3. context exact
                                                                                  ely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                  kind
                                                                                  age
                                                                                  polarity
                                                                                  not_inferred
                                                                                  span
                                                                                  end
                                                                                  2691
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  6 years of age
                                                                                  label id
                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                  start
                                                                                  2677
                                                                                regulatory links
                                                                                  schema version
                                                                                  0.1.0
                                                                                  source batch sha256
                                                                                  bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                  source defined aliases
                                                                                    source span
                                                                                    end
                                                                                    2702
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
                                                                                    label id
                                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                    start
                                                                                    2536
                                                                                    source url
                                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                    spl effective date
                                                                                    2025-10-31
                                                                                    spl set id
                                                                                    4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                    spl version
                                                                                    6
                                                                                    structured fields status
                                                                                    not_extracted_no_values_inferred_from_mentions
                                                                                    structured indication
                                                                                    age
                                                                                    Source null
                                                                                    approval pathway
                                                                                    Source null
                                                                                    biomarker and test
                                                                                    Source null
                                                                                    disease stage
                                                                                    Source null
                                                                                    limitations
                                                                                    Source null
                                                                                    line
                                                                                    Source null
                                                                                    prior therapy
                                                                                    Source null
                                                                                    regimen
                                                                                    Source null
                                                                                    tumor histology
                                                                                    Source null
                                                                                    use intent
                                                                                    non_oncology_or_unclear_candidate
                                                                                    Passage 20 · positive indication candidate
                                                                                    application numbers
                                                                                    1. BLA761216
                                                                                    brand names
                                                                                    1. YUSIMRY
                                                                                    classification reasons
                                                                                    1. explicit_positive_indication_predicate
                                                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                                                    clinical review status
                                                                                    pending
                                                                                    content role
                                                                                    positive_indication_candidate
                                                                                    context span
                                                                                    end
                                                                                    3035
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    h active ankylosing spondylitis. 1.5 Crohn's Disease YUSIMRY is indicated for the treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ]. 1.7 Pla
                                                                                    label id
                                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                    start
                                                                                    2503
                                                                                    current approval status
                                                                                    not_reconciled
                                                                                    duplicate text group
                                                                                    dup-2412de336c5f34540d28
                                                                                    extraction review status
                                                                                    automated_candidate_pending_source_review
                                                                                    generic names
                                                                                    1. ADALIMUMAB-AQVH
                                                                                    id
                                                                                    ind-span-c799f9e4dd657d65e63b
                                                                                    label id
                                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                    positive predicate support span
                                                                                    end
                                                                                    2746
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    is indicated
                                                                                    label id
                                                                                    5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                    start
                                                                                    2734
                                                                                    qualifier mentions
                                                                                    1. context exact
                                                                                      ment of moderately to severely active ulcerative colitis in adult patients.
                                                                                      kind
                                                                                      age
                                                                                      polarity
                                                                                      not_inferred
                                                                                      span
                                                                                      end
                                                                                      2834
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      adult patients
                                                                                      label id
                                                                                      5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                      start
                                                                                      2820
                                                                                    regulatory links
                                                                                      schema version
                                                                                      0.1.0
                                                                                      source batch sha256
                                                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                      source defined aliases
                                                                                        source span
                                                                                        end
                                                                                        2835
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients.
                                                                                        label id
                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                        start
                                                                                        2703
                                                                                        source url
                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                        spl effective date
                                                                                        2025-10-31
                                                                                        spl set id
                                                                                        4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                        spl version
                                                                                        6
                                                                                        structured fields status
                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                        structured indication
                                                                                        age
                                                                                        Source null
                                                                                        approval pathway
                                                                                        Source null
                                                                                        biomarker and test
                                                                                        Source null
                                                                                        disease stage
                                                                                        Source null
                                                                                        limitations
                                                                                        Source null
                                                                                        line
                                                                                        Source null
                                                                                        prior therapy
                                                                                        Source null
                                                                                        regimen
                                                                                        Source null
                                                                                        tumor histology
                                                                                        Source null
                                                                                        use intent
                                                                                        non_oncology_or_unclear_candidate
                                                                                        Passage 21 · limitation of use
                                                                                        application numbers
                                                                                        1. BLA761216
                                                                                        brand names
                                                                                        1. YUSIMRY
                                                                                        classification reasons
                                                                                        1. negative_or_not_established_clause
                                                                                        clinical review status
                                                                                        pending
                                                                                        content role
                                                                                        limitation_of_use
                                                                                        context span
                                                                                        end
                                                                                        3227
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis YUSIMRY is indicated for the treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ]. 1.7 Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other
                                                                                        label id
                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                        start
                                                                                        2636
                                                                                        current approval status
                                                                                        not_reconciled
                                                                                        duplicate text group
                                                                                        dup-4bd2ad565bc657f00e91
                                                                                        extraction review status
                                                                                        automated_candidate_pending_source_review
                                                                                        generic names
                                                                                        1. ADALIMUMAB-AQVH
                                                                                        id
                                                                                        ind-span-a50b93964e6c983a9e60
                                                                                        label id
                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                        positive predicate support span
                                                                                        Source null
                                                                                        qualifier mentions
                                                                                          regulatory links
                                                                                            schema version
                                                                                            0.1.0
                                                                                            source batch sha256
                                                                                            bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                            source defined aliases
                                                                                              source span
                                                                                              end
                                                                                              3027
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ].
                                                                                              label id
                                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                              start
                                                                                              2836
                                                                                              source url
                                                                                              https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                              spl effective date
                                                                                              2025-10-31
                                                                                              spl set id
                                                                                              4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                              spl version
                                                                                              6
                                                                                              structured fields status
                                                                                              not_extracted_no_values_inferred_from_mentions
                                                                                              structured indication
                                                                                              age
                                                                                              Source null
                                                                                              approval pathway
                                                                                              Source null
                                                                                              biomarker and test
                                                                                              Source null
                                                                                              disease stage
                                                                                              Source null
                                                                                              limitations
                                                                                              Source null
                                                                                              line
                                                                                              Source null
                                                                                              prior therapy
                                                                                              Source null
                                                                                              regimen
                                                                                              Source null
                                                                                              tumor histology
                                                                                              Source null
                                                                                              use intent
                                                                                              not_applicable
                                                                                              Passage 22 · positive indication candidate
                                                                                              application numbers
                                                                                              1. BLA761216
                                                                                              brand names
                                                                                              1. YUSIMRY
                                                                                              classification reasons
                                                                                              1. explicit_positive_indication_predicate
                                                                                              2. no_tumor_directed_keyword_in_positive_statement
                                                                                              clinical review status
                                                                                              pending
                                                                                              content role
                                                                                              positive_indication_candidate
                                                                                              context span
                                                                                              end
                                                                                              3477
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              tients. Limitations of Use The effectiveness of adalimumab products has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 ) ]. 1.7 Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YU
                                                                                              label id
                                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                              start
                                                                                              2828
                                                                                              current approval status
                                                                                              not_reconciled
                                                                                              duplicate text group
                                                                                              dup-25621280492a35093671
                                                                                              extraction review status
                                                                                              automated_candidate_pending_source_review
                                                                                              generic names
                                                                                              1. ADALIMUMAB-AQVH
                                                                                              id
                                                                                              ind-span-40386304e3cf10f55e1d
                                                                                              label id
                                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                              positive predicate support span
                                                                                              end
                                                                                              3069
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              is indicated
                                                                                              label id
                                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                              start
                                                                                              3057
                                                                                              qualifier mentions
                                                                                              1. context exact
                                                                                                Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                                                                                kind
                                                                                                age
                                                                                                polarity
                                                                                                not_inferred
                                                                                                span
                                                                                                end
                                                                                                3105
                                                                                                end exclusive
                                                                                                true
                                                                                                exact text
                                                                                                adult patients
                                                                                                label id
                                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                offset unit
                                                                                                unicode_code_points
                                                                                                source array index
                                                                                                0
                                                                                                source field
                                                                                                indications_and_usage_exact
                                                                                                source text sha256
                                                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                start
                                                                                                3091
                                                                                              regulatory links
                                                                                                schema version
                                                                                                0.1.0
                                                                                                source batch sha256
                                                                                                bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                source defined aliases
                                                                                                  source span
                                                                                                  end
                                                                                                  3277
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  1.7 Plaque Psoriasis YUSIMRY is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                                                                                  label id
                                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                  start
                                                                                                  3028
                                                                                                  source url
                                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                                  spl effective date
                                                                                                  2025-10-31
                                                                                                  spl set id
                                                                                                  4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                                  spl version
                                                                                                  6
                                                                                                  structured fields status
                                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                                  structured indication
                                                                                                  age
                                                                                                  Source null
                                                                                                  approval pathway
                                                                                                  Source null
                                                                                                  biomarker and test
                                                                                                  Source null
                                                                                                  disease stage
                                                                                                  Source null
                                                                                                  limitations
                                                                                                  Source null
                                                                                                  line
                                                                                                  Source null
                                                                                                  prior therapy
                                                                                                  Source null
                                                                                                  regimen
                                                                                                  Source null
                                                                                                  tumor histology
                                                                                                  Source null
                                                                                                  use intent
                                                                                                  non_oncology_or_unclear_candidate
                                                                                                  Passage 23 · risk or warning
                                                                                                  application numbers
                                                                                                  1. BLA761216
                                                                                                  brand names
                                                                                                  1. YUSIMRY
                                                                                                  classification reasons
                                                                                                  1. risk_or_warning_words_without_positive_predicate
                                                                                                  clinical review status
                                                                                                  pending
                                                                                                  content role
                                                                                                  risk_or_warning
                                                                                                  context span
                                                                                                  end
                                                                                                  3645
                                                                                                  end exclusive
                                                                                                  true
                                                                                                  exact text
                                                                                                  treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis YUSIMRY is indicated for the treatment of non-infecti
                                                                                                  label id
                                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                  offset unit
                                                                                                  unicode_code_points
                                                                                                  source array index
                                                                                                  0
                                                                                                  source field
                                                                                                  indications_and_usage_exact
                                                                                                  source text sha256
                                                                                                  636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                  start
                                                                                                  3078
                                                                                                  current approval status
                                                                                                  not_reconciled
                                                                                                  duplicate text group
                                                                                                  dup-6b800530108a29cc8fd9
                                                                                                  extraction review status
                                                                                                  automated_candidate_pending_source_review
                                                                                                  generic names
                                                                                                  1. ADALIMUMAB-AQVH
                                                                                                  id
                                                                                                  ind-span-5f27564a0253fadcb620
                                                                                                  label id
                                                                                                  5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                  positive predicate support span
                                                                                                  Source null
                                                                                                  qualifier mentions
                                                                                                    regulatory links
                                                                                                      schema version
                                                                                                      0.1.0
                                                                                                      source batch sha256
                                                                                                      bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                      source defined aliases
                                                                                                        source span
                                                                                                        end
                                                                                                        3445
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ].
                                                                                                        label id
                                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                        start
                                                                                                        3278
                                                                                                        source url
                                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                                        spl effective date
                                                                                                        2025-10-31
                                                                                                        spl set id
                                                                                                        4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                                        spl version
                                                                                                        6
                                                                                                        structured fields status
                                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                                        structured indication
                                                                                                        age
                                                                                                        Source null
                                                                                                        approval pathway
                                                                                                        Source null
                                                                                                        biomarker and test
                                                                                                        Source null
                                                                                                        disease stage
                                                                                                        Source null
                                                                                                        limitations
                                                                                                        Source null
                                                                                                        line
                                                                                                        Source null
                                                                                                        prior therapy
                                                                                                        Source null
                                                                                                        regimen
                                                                                                        Source null
                                                                                                        tumor histology
                                                                                                        Source null
                                                                                                        use intent
                                                                                                        not_applicable
                                                                                                        Passage 24 · positive indication candidate
                                                                                                        application numbers
                                                                                                        1. BLA761216
                                                                                                        brand names
                                                                                                        1. YUSIMRY
                                                                                                        classification reasons
                                                                                                        1. explicit_positive_indication_predicate
                                                                                                        2. no_tumor_directed_keyword_in_positive_statement
                                                                                                        clinical review status
                                                                                                        pending
                                                                                                        content role
                                                                                                        positive_indication_candidate
                                                                                                        context span
                                                                                                        end
                                                                                                        3699
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        are medically less appropriate. YUSIMRY should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.
                                                                                                        label id
                                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                        start
                                                                                                        3246
                                                                                                        current approval status
                                                                                                        not_reconciled
                                                                                                        duplicate text group
                                                                                                        dup-4df26e7ea749eed25ec8
                                                                                                        extraction review status
                                                                                                        automated_candidate_pending_source_review
                                                                                                        generic names
                                                                                                        1. ADALIMUMAB-AQVH
                                                                                                        id
                                                                                                        ind-span-f384cc4343696774ef9d
                                                                                                        label id
                                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                        positive predicate support span
                                                                                                        end
                                                                                                        3495
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        is indicated
                                                                                                        label id
                                                                                                        5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                        start
                                                                                                        3483
                                                                                                        qualifier mentions
                                                                                                        1. context exact
                                                                                                          treatment of moderate to severe hidradenitis suppurativa in adult patients.
                                                                                                          kind
                                                                                                          age
                                                                                                          polarity
                                                                                                          not_inferred
                                                                                                          span
                                                                                                          end
                                                                                                          3578
                                                                                                          end exclusive
                                                                                                          true
                                                                                                          exact text
                                                                                                          adult patients
                                                                                                          label id
                                                                                                          5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                          offset unit
                                                                                                          unicode_code_points
                                                                                                          source array index
                                                                                                          0
                                                                                                          source field
                                                                                                          indications_and_usage_exact
                                                                                                          source text sha256
                                                                                                          636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                          start
                                                                                                          3564
                                                                                                        regulatory links
                                                                                                          schema version
                                                                                                          0.1.0
                                                                                                          source batch sha256
                                                                                                          bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                          source defined aliases
                                                                                                            source span
                                                                                                            end
                                                                                                            3579
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients.
                                                                                                            label id
                                                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                            start
                                                                                                            3446
                                                                                                            source url
                                                                                                            https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                                            spl effective date
                                                                                                            2025-10-31
                                                                                                            spl set id
                                                                                                            4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                                            spl version
                                                                                                            6
                                                                                                            structured fields status
                                                                                                            not_extracted_no_values_inferred_from_mentions
                                                                                                            structured indication
                                                                                                            age
                                                                                                            Source null
                                                                                                            approval pathway
                                                                                                            Source null
                                                                                                            biomarker and test
                                                                                                            Source null
                                                                                                            disease stage
                                                                                                            Source null
                                                                                                            limitations
                                                                                                            Source null
                                                                                                            line
                                                                                                            Source null
                                                                                                            prior therapy
                                                                                                            Source null
                                                                                                            regimen
                                                                                                            Source null
                                                                                                            tumor histology
                                                                                                            Source null
                                                                                                            use intent
                                                                                                            non_oncology_or_unclear_candidate
                                                                                                            Passage 25 · positive indication candidate
                                                                                                            application numbers
                                                                                                            1. BLA761216
                                                                                                            brand names
                                                                                                            1. YUSIMRY
                                                                                                            classification reasons
                                                                                                            1. explicit_positive_indication_predicate
                                                                                                            2. no_tumor_directed_keyword_in_positive_statement
                                                                                                            clinical review status
                                                                                                            pending
                                                                                                            content role
                                                                                                            positive_indication_candidate
                                                                                                            context span
                                                                                                            end
                                                                                                            3699
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            up visits with a physician [see Warnings and Precautions ( 5 ) ]. 1.8 Hidradenitis Suppurativa YUSIMRY is indicated for the treatment of moderate to severe hidradenitis suppurativa in adult patients. 1.9 Uveitis YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.
                                                                                                            label id
                                                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                            start
                                                                                                            3380
                                                                                                            current approval status
                                                                                                            not_reconciled
                                                                                                            duplicate text group
                                                                                                            dup-a42ba2d185cfa87ac636
                                                                                                            extraction review status
                                                                                                            automated_candidate_pending_source_review
                                                                                                            generic names
                                                                                                            1. ADALIMUMAB-AQVH
                                                                                                            id
                                                                                                            ind-span-cf763bbddce0f121361e
                                                                                                            label id
                                                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                            positive predicate support span
                                                                                                            end
                                                                                                            3612
                                                                                                            end exclusive
                                                                                                            true
                                                                                                            exact text
                                                                                                            is indicated
                                                                                                            label id
                                                                                                            5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                            offset unit
                                                                                                            unicode_code_points
                                                                                                            source array index
                                                                                                            0
                                                                                                            source field
                                                                                                            indications_and_usage_exact
                                                                                                            source text sha256
                                                                                                            636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                            start
                                                                                                            3600
                                                                                                            qualifier mentions
                                                                                                            1. context exact
                                                                                                              f non-infectious intermediate, posterior, and panuveitis in adults.
                                                                                                              kind
                                                                                                              age
                                                                                                              polarity
                                                                                                              not_inferred
                                                                                                              span
                                                                                                              end
                                                                                                              3698
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              adults
                                                                                                              label id
                                                                                                              5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                              start
                                                                                                              3692
                                                                                                            regulatory links
                                                                                                              schema version
                                                                                                              0.1.0
                                                                                                              source batch sha256
                                                                                                              bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
                                                                                                              source defined aliases
                                                                                                                source span
                                                                                                                end
                                                                                                                3699
                                                                                                                end exclusive
                                                                                                                true
                                                                                                                exact text
                                                                                                                1.9 Uveitis YUSIMRY is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.
                                                                                                                label id
                                                                                                                5c419a4b-5654-43dc-aefb-9e8e86bd5761
                                                                                                                offset unit
                                                                                                                unicode_code_points
                                                                                                                source array index
                                                                                                                0
                                                                                                                source field
                                                                                                                indications_and_usage_exact
                                                                                                                source text sha256
                                                                                                                636196b6ffb068de48b3aafedb2033ea9dfd6a1d7371c0959afcbbcdff4f587c
                                                                                                                start
                                                                                                                3580
                                                                                                                source url
                                                                                                                https://api.fda.gov/drug/label.json?search=id%3A%225c419a4b-5654-43dc-aefb-9e8e86bd5761%22
                                                                                                                spl effective date
                                                                                                                2025-10-31
                                                                                                                spl set id
                                                                                                                4cab600d-6950-409f-a6d8-d447da22cd95
                                                                                                                spl version
                                                                                                                6
                                                                                                                structured fields status
                                                                                                                not_extracted_no_values_inferred_from_mentions
                                                                                                                structured indication
                                                                                                                age
                                                                                                                Source null
                                                                                                                approval pathway
                                                                                                                Source null
                                                                                                                biomarker and test
                                                                                                                Source null
                                                                                                                disease stage
                                                                                                                Source null
                                                                                                                limitations
                                                                                                                Source null
                                                                                                                line
                                                                                                                Source null
                                                                                                                prior therapy
                                                                                                                Source null
                                                                                                                regimen
                                                                                                                Source null
                                                                                                                tumor histology
                                                                                                                Source null
                                                                                                                use intent
                                                                                                                non_oncology_or_unclear_candidate

                                                                                                                Preserved source evidence · Not medical advice